Clinical Trial Update: Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

GenSight Biologics is conducting a dose-escalation Phase 1/2 trial of GS030 to evaluate safety and tolerability in non-syndromic Retinitis Pigmentosa. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• GS030

Snippet

Sponsor: GenSight Biologics | Conditions: Non-syndromic Retinitis Pigmentosa | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING